Wall Street was busy on the last day of 2014.
So, what should traders watch to start the New Year?
Honeywell International
Honeywell International Inc. (NYSE: HON) recently saw Jefferies reiterate its Buy rating on the company. The firm also boosted its price target from $105 to $115, on the back of a strong outlook for 2015.
JP Morgan and Stifel Nicolaus are optimistic on Honeywell's prospects as well. On December 18, JP Morgan issued an Overweight recommendation and a $105 price target, while Stifel reiterated a Buy rating and a $112 target on December 16.
Honeywell shares currently trade near $100.
Southwestern Energy
Wall Street also seems quite fond of Southwestern Energy Company (NYSE: SWN), the natural gas and oil exploration company.
On December 31, Imperial Capital reiterated its Outperform rating on the stock, along with a $43 price target. That implies an upside of more than 50 percent from current share prices.
On December 30, Capital One Financial upgraded the stock from Equalweight to Overweight with a $41 target.
Related Topic: Despite Oil Glut, Southwestern Energy To Boost Production
Methanex
Methanex Corporation (NASDAQ: MEOH), the mid-cap methanol supplier, is another name to watch.
On Wednesday, Monness Crespi Hardt issued a Buy rating and a $64 price target. Earlier in December, TD Securities and UBS both issued Buy ratings with $60 and $68 price targets.
Methanex stock now trades around $46.40.
Esterline Technologies
Esterline Technologies Corporation (NYSE: ESL) received its first rating since Q3 on the last day of Q4. Jefferies rated the stock as a Buy with a $132 price target, implying an 18 percent upside potential from existing share prices.
Esterline designs, manufactures and markets highly engineered products for the aerospace and defense industry, mainly in the United States and Europe. Its market cap is near $3.5 billion.
Cempra
Cempra, Inc. (NASDAQ: CEMP), lastly, belongs among these names. Analysts at Stifel maintained a Buy rating on Wednesday, raising their price target on Cempra from $22 to $33, citing a good risk/reward profile.
"We believe recent acquisition multiples in what is proving to be a rapidly-consolidating antibiotic space comfortably support a 2-3x higher valuation," Stifel said.
Cempra shares currently trade near $23.
Latest Ratings for HON
| Dec 2014 | Jefferies | Maintains | Buy | |
| Dec 2014 | JP Morgan | Maintains | Overweight | |
| Dec 2014 | Stifel Nicolaus | Maintains | Buy |
View More Analyst Ratings for HON
View the Latest Analyst Ratings
See more from Benzinga
-
GrubHub Rises Following Upgrade: A Look At 2 Other Mobile App Stocks
-
Civeo Loses More Than 50%; What Are Some Other Stocks In the Business Services Industry?
-
Cnova Ends Quiet Period; What Other Stocks Do Analysts Like?
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.